JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabeticretinopathy.
Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabeticretinopathy [1].
Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabeticretinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen species generation and stress fiber forma